Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)

NCT04655976 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04655976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04655976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 8, 2020
Completion date
March 30, 2027
Enrollment
758 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell